VBI Vaccines Inc.

VBI Vaccines — Investor Presentation (June 2018)

35 slides from VBI Vaccines's investor presentation, Jun 6, 2018

  1. Slide 1: VBI Vaccines Corporate

    Willa, “> VBI VACCINES CORPORATE NASDAQ: VBIV JUNE 2018

  2. Slide 2: Cautionary Statement Regarding Forward-Looking Information

    Cautionary Statement Regarding Forward-Looking Information Certain statements in this presentation that are forward-looking and not statements of historical fact are forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 an

  3. Slide 3: pie

    pie SS + évbiz ae NASDAQ; VBIV 3

  4. Slide 4: VBI Vaccines Global Footprint

    VBI Vaccines Global Footprint mew Portugal Mgt eau ‘Spain North | > HEADQUARTERS — CAMBRIDGE, MA = CEO, CSO, CBO + 3 FTEs = Central location in biotechnology hub RESEARCH OPERATIONS — OTTAWA, CANADA = CMO, Finance + ~25 FTEs = World-class R&D team and facility MANUFACTURING FACILITY — REHOVOT, ISRAE

  5. Slide 5: VBI Vaccines Leadership

    VBI Vaccines Leadership MANAGEMENT Se re Jeff Baxter zu 4 E Ulan S Dr. Francisco Diaz-Mitoma, M.D., Ph.D. President & CEO cmosminsin GROUP Chief Medical Officer e Dr. David Anderson, Ph.D. HARVARD Nell Beattie ARTISAN Chief Scientific Officer meee Chief Business Officer a ck Schoo of Business BOARD

  6. Slide 6: VBI Vaccines Pipeline

    VBI Vaccines Pipeline Multiple Opportunities in Infectious Disease and Oncology LEAD PRE-CLINICAL PHASE! = PHASEIl = PHASE IIl_ “APPROVED STATUS INFECTIOUS DISEASE ; an Enrolling Phase III @ Sci-B-Vac® (Hepatitis B) Topline Ph Ill data (Licensed in 15 countries) expected mid-2019 IMMUNO-ONCOLOGY Top

  7. Slide 7: Recent Key Achievements

    Recent Key Achievements JULY 2017 — MAY 2018 May 2018 Announcement of positive topline results from CMV Phase | study April 2018 Completion of enrollment in PROTECT Phase III study for Sci-B-Vac® (Hepatitis B) . Positive DSMB review in Phase I/Ila study of VBI-1901 (GBM) and initiation of enrollment

  8. Slide 8: Sci-B-Vac: Hepatitis B

    alm, SS 2. Sci-B-Vac®: Hepatitis B Y C7 ~ svbiz we NASDAQ: VBIV 8

  9. Slide 9: Hepatitis B Unmet Need

    OOOO eee Hepatitis B Unmet Need Reported US H is B Vaccination Coverage — 2015 (23 doses) Otherwise Healthy Adults aged 2 19 years 24.6% Adults aged 19-49 years 32.0% Adults age > 50 years 16.5% High-Risk Chronic Liver Conditions 27.4% Diabetics — Age 19-59 years 24.4% Diabetics — Age = 60 years 12.

  10. Slide 10: Existing High Unmet Need in Specific Populations

    OOOO eee Existing High Unmet Need in Specific Populations SEROCONVERSION RATES WITH CURRENT VACCINES FALL DRAMATICALLY WITHIN THE ELDERLY AND HIGH-RISK PATIENT POPULATIONS Anti-HBs Seroconversion Rates After Hepatitis B Vaccination Neonates >95% Age 2-19 ~99% Age 20-29 ~95% Age 30 - 39 ~90% Age 40 -

  11. Slide 11: Sci-B-Vac Overview

    Sci-B-Vac® Overview ONLY COMMERCIAL HBV VACCINE KNOWN TO MIMIC ALL THREE VIRAL SURFACE ANTIGENS — ALREADY SAFELY USED IN 500,000+ PATIENTS * Sci-B-Vac® achieves rapid onset of protection, with high levels of anti-HBV antibodies (HBsAb), at a lower dosage than competing vaccines 2° GENERATION VACCINE

  12. Slide 12: Sci-B-Vac Existing Safety and Efficacy Data Package

    OOOO eee Sci-B-Vac® Existing Safety and Efficacy Data Package EXTENSIVE CLINICAL DEVELOPMENT SUPPORTS PHASE III DESIGN * Product distribution data globally estimates that over 500,000 infants and adults have been vaccinated with Sci-B-Vac® * Inthe last two decades, 22 clinical trials have been compl

  13. Slide 13: Sci-B-Vac Demonstrated Superior Seroprotection Rates in Older Adults

    Sci-B-Vac® Demonstrated Superior Seroprotection Rates in Older Adults Stratification by Age of Study 38-96-040 Demonstrates Significantly Improved Potency in Older Adults Seroprotection Stratified by Age Percent HBsAg Seroprotection 100.0% 95.0% 90.0% 85.0% 80.0% 75.0% 70.0% 65.0% 60.0% 55.0% 50.0%

  14. Slide 14: Interim Data from Israeli Phase IV Study

    Interim Data from Israeli Phase IV Study Reinforces Strength of Sci- B-Vac® Potency in Adult Populations & Potential for Rapid Seroprotection SCI-B-VAC® PHASE IV STUDY IN ISRAELI ADULTS (AGE 18-40, N=88) SEROPROTECTION (>10 IU/ML) 100% 80% 60% 40% 20% 0% Month 1 Month 2 Month 3 30-days post 1 vaccin

  15. Slide 15: Phase III Clinical Program

    OOOO eee Phase III Clinical Program Target Population: “4,800 adults age 18 years and older * Expected Duration: 15 Months * Clinical Trial Sites: ~40 sites across the US, Europe, and Canada * Design: Two concurrent Phase Ill studies: 1. PROTECT : Safety and immunogenicity study (n=1,600) 2. CONSTAN

  16. Slide 16: eVLP Portfolio Programs

    \\ 3. eVLP Portfolio Programs + évbiz ae NASDAQ; VBIV 16

  17. Slide 17: eVLPs are a 3rd-Generation Class of Synthetic Vaccines

    OOOO eee eVLPs are a 3'4-Generation Class of Synthetic Vaccines = eVLPs are the same size and structure as enveloped viruses; present antigens in their natural state for an improved immune response = The foundation of the eVLP Platform is a stable, protein-based core on which additional vaccine anti

  18. Slide 18: eVLP Portfolio Programs: CMV

    wl 3. eVLP Portfolio Programs Y a. CMV AUf|\\\ ~ €vbi NASDAQ; VBIV 18

  19. Slide 19: Congenital CMV is a Leading Public Health Priority

    Congenital CMV is a Leading Public Health Priority U.S. CHILDREN BORN WITH OR DEVELOPING LONG-TERM MEDICAL CONDITIONS Congenital CMV Disease Fetal Alcohol Syndrome Down Syndrome Spina Bifida / Anencephaly Pediatric HIV / AIDS Invasive Hib ie) 1,000 than Down Syndrome CMV affects more live births or

  20. Slide 20: Congenital CMV is a Leading Public Health Priority

    OOOO eee Congenital CMV is a Leading Public Health Priority = Each year, approximately 30,000 infants are born with CMV infection, of which 5,000+ U.S. infants will develop permanent problems including deafness, blindness, and developmental delays = Inthe U.S., the direct economic costs of CMV infec

  21. Slide 21: eVLP Presentation Improves CMV Vaccine Potency

    eVLP Presentation Improves CMV Vaccine Potency Presentation of gB antigen in an eVLP improves relevant functional CMV neutralizing responses relative to recombinant gB protein PRECLINICAL RESULTS ¢ Neutralizing antibodies (nAb) are the desired functional immune response for prophylaxis ¢ gB in eVLP

  22. Slide 22: CMV Phase I Clinical Study Overview

    CMV Phase | Clinical Study Overview Opportunity for Immunologic Human Proof of Concept with Ph | Data STUDY DESIGN m= Target Population: 128 CMV-Negative Healthy Adults (18-40 yrs) Design: Staggered Enrollment with Vaccinations at 0, 2, and 6 Months Duration: 20 Months Interim Data Read-Out: Based o

  23. Slide 23: gB Antibody Binding Titers - Kinetics

    OOOO eee gB Antibody Binding Titers - Kinetics Anti-gB Endpoint Titer (1/X) “® VBI-1501A (2ug gB) 4 VBI-1501A (1g gB) 2% VBI-1501A (0.5ug gB) + VBI-1501 (tug) 10 10 10 0 28 56 84 112 140 168 196 224 252 280 308 336 Days t t t Vaccine immunizations NASDAQ; VBIV 23

  24. Slide 24: Fibroblast Cell nAb Seroconversion Rate

    Fibroblast Cell nAb Seroconversion Rate 100% nAb response 1 month after 3" 2ng dose of VBI-1501A = <7 2 2 100 ; g HM CM\V* Healthy Subjects 5 15 Hl VBI-1501A (2ug gB) s ES] VBI-1501A (11g gB) g 50 VBI-1501A (0.5yg gB) 2 3 VBI-1501 (1yg gB) c 25: 7) & 0 2 2 2 wu RS ca * The GMT for CMV* sera was 237

  25. Slide 25: Correlation Between gB Binding Titers & nAb Activity

    OOOO eee Correlation Between gB Binding Titers & nAb Activity * The highest dose of VBI-1501A (21g) demonstrated a 31% neutralizing antibody seroconversion rate after three vaccinations, up from 17% after two vaccinations * The epithelial cell neutralizing activity was associated with higher binding

  26. Slide 26: Summary of Final Phase I Study Results

    OOOO eee Summary of Final Phase | Study Results VBI-1501A is safe and well tolerated at all doses tested, with no concern about evaluating VBI-1501A at higher doses VBI-1501A is immunogenic, even at a low dose © gB antibody binding titers induced at all dose levels, with clear evidence of dose- depe

  27. Slide 27: eVLP Portfolio Programs: GBM

    tt S 2 3. eVLP Portfolio Programs Y b. GBM 7Upf\\ + €vbi NASDAQ: VBIV 27

  28. Slide 28: Therapeutic GBM Candidate Builds on Prophylactic CMV Candidate

    Therapeutic GBM Candidate Builds on Prophylactic CMV Candidate (VBI-1501A) by Adding an Internal pp65 Protein to Elicit a Th1 Response Attributes gB Envelope pp65 ‘Foreign’ ‘Foreign’ Viral Antigen Viral Antigen Bivalent — pp65 for Therapeutic Immuno- Monovalent gB for Prophylaxis loncalony, Present

  29. Slide 29: Poor Immunogenicity of Traditional Tumor-Associated Antigens

    Poor Immunogenicity of Traditional Tumor-Associated Antigens (TAAs) has Limited Past Therapeutic Cancer Vaccines IMMUNOGENICITY LOW ——————————______—_—_—————> HIGH VIRAL CMV ANTIGENS ARE OVER-EXPRESSED (>90%) IN MULTIPLE SOLID TUMORS, INCLUDING: Glioblastoma (GBM) Medulloblastoma?? Meningioma? Breas

  30. Slide 30: VBI-1901: Re-stimulated CD4+ and CD8+ T-cell Responses

    VBI-1901: Re-stimulated CD4+ and CD8+ T-cell Responses in CMV-positive Human Subject Ex Vivo RESTIMULATION OF CD4* & CD8* T-CELLS IN * Fresh PBMCs stimulated EX VIVO HUMAN SAMPLES with VBI-1901 vs = cpateN.y* CD8*FN-;* recombinant antigens © 25 ° : i * eVLPs rapidly restimulate a 2.0 2 both CD4+ & C

  31. Slide 31: VBI-1901 Induction of CCL3 in Ex Vivo PBMCs

    VBI-1901 Induction of CCL3 in Ex Vivo PBMCs from CMV-positive Healthy Subjects and Patients with Solid Tumors CCL3 Secretion £ g > 25 15 cs SR c ow S a ® 3 B= 10 3 act oo Se 2 e o Sam 5 ° be a 52 3 ae ao o x 3 & s es s se = re) Ss NY ¥ & * PBMCs from CMV+ healthy subjects or patients with GBM, medul

  32. Slide 32: GBM Phase I/IIa Clinical Study Overview

    GBM Phase I/Ila Clinical Study Overview TRIAL DESIGN * Two-part, multi-center, open-label, dose-escalation study of VBI-1901 in patients with recurrent GBM (rGBM) ¢ PartA: * Dose-escalation phase to define the safety, tolerability, and optimal dose level of VBI-1901 * N=up to 18 patients ¢ First pat

  33. Slide 33: Summary

    wn 4. Summary + svbiz ee NASDAQ: VBIV 33

  34. Slide 34: Value Proposition for VBI Vaccines

    ee, \\ ee Value Proposition for VBI Vaccines KEY VALUE DRIVERS IN NEXT 18 MONTHS: @ Sci-B-Vac®: Phase Ill Program in the U.S., Europe, and Canada Enrollment initiated in Q4 2017, headline results expected mid-2019 @ CMV: Phase | Clinical Study Topline results announced May 2018, discussions with reg

  35. Slide 35: VBI Vaccines Contact

    wm, i) — = — =vbi — Ss Y 7M “iif\ VBI Vaccines Inc. 222 Third Street, Suite 2241 Cambridge, MA 02142 (617) 830-3031 info@vbivaccines.com

VBI Vaccines — Investor Presentation (June 2018) on 6ix